TRIPS and Access to Medicines
Page 1: Introduction
Title: TRIPS, Public Health and Access to Medicines
Course: LACM14 International Intellectual Property Law 2024/2025
Instructor: Dr Lowri Davies
Page 2: Weekly Overview
Main Topics:
Exceptions to patent protection
Context of TRIPS and public health
Access to medicines/vaccines debate
Page 3: Recap on Patents
Key Points:
Patentability criteria overview
Excluded subject matter under patent law
Discussion of exceptions to patent protection
Page 4: Patents and Public Health: Introduction
Introduction to the debate on patents and access to medicines post-TRIPS implementation.
Role of Patents:
Significant impact on access to lifesaving medicines.
Patent holders can set prices without competition, which may restrict access to medicines for individuals in developing countries.
Page 5: Patents and Public Health: Historical Context
HIV/AIDS Pandemic Impact:
Highlighted issues of access to antiretroviral drugs in developing countries, especially Africa.
COVID-19 Pandemic:
Renewed discussions on patents and vaccine accessibility.
Page 6: Perspectives on Patents
Counterthink Concept
Visual representation of the conflict between patent rights and patient rights with imagery of lifeboats (drugs) owned by companies.
Page 7: Stakeholders in the Discussion
Different Perspectives:
International Organizations: WIPO, WTO, WHO
Charitable and Humanitarian Organizations
Pharmaceutical Industry
Different State Perspectives: Developed vs. Developing Countries
Page 8: Pharmaceutical Industry Perspective
Innovation Costs:
Patents provide temporary market exclusivity to recoup R&D costs.
Risk:
Without patents, generic manufacturers could easily copy existing medicines, hurting original creators financially.
Page 9: Social Contract of Patents
Patent Protection:
Society grants patents with the expectation of innovation that will benefit consumers in the long term despite short-term higher prices.
Public Health Concerns:
Unclear if this assumption holds true, especially regarding pharmaceuticals.
Page 10: WHO and Public Health
WHO’s Strategy:
Global Strategy and Plan of Action adopted in 2008 concerning Public Health, Innovation, and IP.
Highlights:
Multiple factors affecting access to medicines.
Patent protection influences access to essential medicines.
Need for national incorporation of TRIPS flexibilities.
WHO’s role in offering technical assistance.
Page 11: WIPO's Role
WIPO's Ongoing Work:
Understanding the connections between Global Health and Intellectual Property (IP).
Trilateral study with WTO and WHO on public health, IP, and trade.
Page 12: Access to Medicines Goal
Medicines Availability:
Statement advocating that medicines should not be viewed as luxury items.
Page 13: Affordability of Essential Medicines
Focus on HIV/AIDS:
Urgency in providing treatment for millions needing ARV medicines.
Initial costs versus significant price reductions due to competition.
Broadening Debate:
Discussion extended to other diseases like tuberculosis, cancer, etc.
Page 14: TRIPS Overview of Patents
Core Concept:
Focus on patents and their relation to TRIPS agreements.
Page 15: Patentability and Exclusions
TRIPS Article 27:
Specifies criteria for patentability (novelty, inventive step, industrial application).
Exclusions from Patentability:
To protect public order, morality, and certain medical methods among others.
Page 16: Rights Conferred by Patents
TRIPS Article 28:
Exclusive rights for patent owners include preventing unauthorized use of patents.
Rights to assign, transfer, and license patents included.
Page 17: Exceptions in TRIPS
TRIPS Stipulations:
Allows exceptions for certain uses without patent holder's permission.
Governed by Articles 30 and 31.
National Implementation:
Implemented under various national laws.
Page 18: Purpose of Exceptions
Balancing Interests:
Need to balance innovation incentives with public access.
Adaptation of Flexibilities:
TRIPS allows nations to meet social development goals, enhance public health.
Page 19: In-depth on Article 30
National Exceptions:
Members may provide limited exceptions to patent rights if they do not harm normal patent exploitation or adversely affect legitimate interests of patent holders.
Page 20: Article 30 Detailed
Conditions of Use:
Conditions detail how exceptions may be employed in a manner that respects intellectual property rights while pursuing public health goals.
Page 21: Case Study: WTO DSB Decision
Panel Decision:
Canada's Patent Protection case explores interpretation of Article 30, allowing for non-voluntary uses for testing generic drugs under specific conditions.
Page 22: Critiques of Article 30 Implementation
Opinions on Balance:
Experts question if the WTO Panel achieved intended balance between IP rights and public health needs, criticizing oversight of Articles 7 and 8 objectives.
Page 23: Uses of Article 30
Research Exceptions:
Common legal reasoning for national laws concerning experimental use and regulatory testing.
Page 24: Overview of Article 31
Compulsory Licensing:
Article 31 allows for third party use of patented inventions without patent holder consent under specific circumstances.
Page 25: Conditions of Article 31
Key Conditions:
Individual evaluations for compulsory licensing; prior negotiations needed with patent holders; mainly for domestic use, barring some exemptions.
Page 26: National Level Examples
Compulsory Licenses Issued:
Thailand and Brazil’s experience with issuing compulsory licenses for HIV/AIDS and heart disease medications.
Page 27: Challenges of Article 31
Implementation Issues:
Concerns about developing countries' ability to meet Article 31's conditions, particularly on local usage requirements.
Page 28: 2001 Doha Declaration
Context and Adoption:
Response to global health crises; recognized challenges faced by countries in utilizing Article 31 flexibly.
Page 29: Doha Declaration Key Points
Article 4 Perspectives:
Stated that TRIPS should be interpreted to support public health and access to medicines, affirming rights of countries to use flexibility in the agreement.
Page 30: Doha Declaration Article 6
Manufacturing Capacity Considerations:
Recognizes varying capacities of countries to utilize Article 31, seeks solutions to facilitate access.
Page 31: WTO Decision on Compulsory Licensing
WTO Framework:
Amended TRIPS to address complications for countries unable to manufacture domestically; waivers for distribution under compulsory licenses introduced.
Page 32: Beneficiaries of New Provisions
Eligibility:
Automatic eligibility for LDCs, with conditions for other nations depending on individual circumstances.
Page 33: Notifications in New Framework
Requirements:
Importing countries must declare intent, and exporting countries provide details of licenses.
Page 34: Safeguards in Utilization
Transparency Requirements:
Strict measures for ensuring traceability and accountability in the export of pharmaceuticals.
Page 35: Implementation of Para 6 System
Contextual Scenarios:
Describe the conditions under which the system can be activated for global health needs.
Page 36: WTO Amendment and Usage Case
Implementation Experience:
Overview of Canada’s role in facilitating trade of ARVs with Rwanda under new regulations.
Page 37: Compulsory Licensing Concerns
Functional Design:
Challenges in AMCR and need for structural changes to broaden scope for developing nations.
Page 38: Compulsory Licensing during Covid
Impact on Global Vaccination:
Examination of how compulsory licensing was invoked, with examples of failed attempts in specific scenarios.
Page 39: Recent Waivers and Notifications
June 2022 Proposal:
Discussion of expanding TRIPS flexibilities based on COVID-19 experiences, addressing critical operational barriers.
Page 40: Ministerial Decision Overview
Key Decisions Adopted:
Options granted to Members to bypass patent rights for COVID-19 vaccine production to expedite market availability.
Page 41: Key Provisions from TRIPS Waiver
Clarifications:
Members are permitted to use patents without rights holder consent in defined scenarios to combat COVID-19.
Page 42: Temporary Waiver's Nature
Limitations and Criticisms:
Limited scope compared to original intentions; focused narrowly on vaccines and specific patent concerns.
Page 43: Alternative Solutions
Potential Approaches:
Patent pooling, COVAX initiatives aimed at broadening accessibility to critical treatments and medicines.
Page 44: Broader Quotations on TRIPS Impact
Framing the Discussion:
Recognizing that many factors beyond patent restrictions influence healthcare outcomes.
Page 45: TRIPS Implementation Issues
Broader Implications:
Need to tackle TRIPS-plus provisions and emphasize technology transfer effectiveness in healthcare.
Page 46: Next Week's Topic
Introduction to New Subject:
Focus shifts to plant varieties and their governance.